GlassScriptPhysician profile
Joseph D Harris
NPI 1275539074
$2,174.24
in general payments reported to CMS, 2019-2025
25 companies · $425 in 2025
The $425 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $81.84 · 2021: $186 · 2022: $368 · 2023: $393 · 2024: $450 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.06 |
| Education | $103.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $488.03 | 2019-2024 | Myrbetriq, Xtandi |
| Abbvie INC. | $429.76 | 2019-2025 | |
| Boston Scientific Corporation | $199.21 | 2020-2025 | Axonics, Ams 700, Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $178.24 | 2023-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $146.28 | 2019-2023 | Aquabeam Robotic System |
| Ferring Pharmaceuticals INC. | $113.52 | 2019-2024 | Adstiladrin |
| Endo USA, INC. | $86.34 | 2025 | Aveed, Xiaflex |
| Janssen Biotech, INC. | $64.50 | 2019-2024 | Erleada |
| Teleflex LLC | $56.62 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $48.64 | 2020-2025 | Keytruda |
| Allergan, INC. | $48.41 | 2021-2022 | |
| Pfizer INC. | $36.34 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Ethicon US, LLC | $27.79 | 2023 | Enseal |
| Myovant Sciences INC. | $25.43 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $24.46 | 2022 | |
| Coloplast Corp | $23.13 | 2023 | Altis |
| Accord Healthcare, INC. | $21.57 | 2025 | |
| Axonics, INC. | $21.18 | 2024 | Axonics |
| Convatec INC. | $20.71 | 2023 | |
| Heron Therapeutics, INC. | $20.21 | 2024 | Zynrelef |
| Cycle Pharmaceuticals INC | $17.57 | 2024 | Tiopronin |
| Acerus Pharmaceuticals Corporation | $14.28 | 2020 | |
| Urovant Sciences INC | $13.51 | 2022 | |
| Cook Medical LLC | $13.45 | 2024 | Ncircle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.